Fig. 19. The antiviral drug ganciclovir is a hydroxylated derivative of acyclovir that has greatly enhanced activity against cytomegalovirus. Oral ganciclovir has poor bioavailability, but the introduction of a prodrug of ganciclovir, valganciclovir, has allowed the achievement of high blood levels of ganciclovir with oral therapy.